Canara Robeco Banking and Financial Services Fund vs Nippon India Pharma Fund
Direct Plan, Growth option · Data as on 30-10-2026
Canara Robeco Banking and Financial Services Fund is a Sectoral fund and Nippon India Pharma Fund is a Sectoral fund. Canara Robeco Banking and Financial Services Fund charges 1.05% a year and Nippon India Pharma Fund 0.99% (Direct plans). Their portfolios overlap 0.0%: they hold 0 of the same securities.
Canara Robeco Banking and Financial Services Fund
Sectoral
- Expense ratio
- 1.05%
- NAV
- ₹10.26
Which is better, Canara Robeco Banking and Financial Services or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Nippon India Pharma costs less: 0.99% a year against 1.05% (Direct plans).
- Nippon India Pharma fell less in its worst fall since 23-03-2026: −9.6% against −10.0%.
- Canara Robeco Banking and Financial Services holds more in large companies: 62.5% of the fund in large caps against 29.7%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹624 Cr.
- Their portfolios overlap 0.0%: 0 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Canara Robeco Banking and Financial Services Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Canara Robeco Mutual Fund | Nippon India Mutual Fund |
| Category | Sectoral | Sectoral |
| AUM | ₹624 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹10.26 (Direct) | ₹625.46 (Direct) |
| Expense ratio (Direct) | 1.05% | 0.99% |
| Expense ratio (Regular) | 2.65% | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | Nifty Financial Services TRI | BSE Healthcare TRI |
| Launch date | 20-03-2026 | 05-06-2004 |
| Minimum investment | ₹5,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Amit Kadam / Mr. Shridatta Bhandwaldar | Sailesh Raj Bhan |
| Exit load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 365 days. | Exit load of 1% if redeemed within 1 month. |
Canara Robeco Banking and Financial Services vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Canara Robeco Banking and Financial Services Fund (Direct) | −1.91% | −5.96% | −1.44% | -- | -- | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
Canara Robeco Banking and Financial Services vs Nippon India Pharma: Year-wise Returns
| Year | Canara Robeco Banking and Financial ServicesCanara Robeco Banking and Financial Services | Nippon India PharmaNippon India Pharma |
|---|---|---|
| 2026to date | -- | +9.76% |
| 2025 | -- | −2.46% |
| 2024 | -- | +35.26% |
| 2023 | -- | +40.36% |
| 2022 | -- | −9.06% |
| 2021 | -- | +25.12% |
Canara Robeco Banking and Financial Services vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against Nifty Financial Services TRI, the benchmark of Canara Robeco Banking and Financial Services Fund
Canara Robeco Banking and Financial Services vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Canara Robeco Banking and Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +6.26% | +17.18% |
| Standard deviation | 15.54% | 15.19% |
| Sharpe ratio | 0.06 | 0.73 |
| Sortino ratio | 0.09 | 1.06 |
| Maximum drawdown | −10.0% (27-10-2026) | −24.0% (29-05-2017) |
| Beta | 0.78 | 0.85 |
| Alpha | −0.14% | +3.72% |
From daily NAVs, 23-03-2026 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Canara Robeco Banking and Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Canara Robeco Banking and Financial Services Fund (Direct) | −10.0% | 31-08-2026 | 27-10-2026 | Not yet | -- | −9.0% |
| Nippon India Pharma Fund (Direct) | −9.6% | 31-08-2026 | 23-10-2026 | Not yet | -- | −4.3% |
| Nifty Financial Services TRI | −9.9% | 03-08-2026 | 27-10-2026 | Not yet | -- | −8.3% |
From daily values since 23-03-2026, the first day every fund has.
Canara Robeco Banking and Financial Services vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: Canara Robeco Banking and Financial Services Fund, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 0.0%
- Held by both
- 0
- Only in Canara Robeco Banking and Financial Services
- 30
- Only in Nippon India Pharma
- 36
Overlap: for each holding both funds own, the smaller of its two weights, added up. 0.0% means 0.0% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Canara Robeco Banking and Financial Services Fund
| Security | % of fund |
|---|---|
| HDFC Bank Ltd | 10.82% |
| ICICI Bank Ltd | 10.32% |
| State Bank of India | 7.45% |
| Axis Bank Ltd | 7.20% |
| Bajaj Finance Ltd | 5.32% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Sun Pharmaceutical Industries Limited | 11.71% |
| Divi's Laboratories Limited | 7.10% |
| Lupin Limited | 6.17% |
| Cipla Limited | 6.01% |
| Dr. Reddy's Laboratories Limited | 5.45% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Canara Robeco Banking and Financial Services | Nippon India Pharma |
|---|---|---|
| Equity | 96.1% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 3.9% | 2.7% |
Market cap of stocks
| Market cap | Canara Robeco Banking and Financial Services | Nippon India Pharma |
|---|---|---|
| Large Cap | 62.5% | 29.7% |
| Mid Cap | 17.0% | 39.0% |
| Small Cap | 16.5% | 28.0% |
| Not on AMFI's list | 0.0% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Canara Robeco Banking and Financial Services | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 0.0% | 74.0% |
| Banks | 52.6% | 0.0% |
| Finance | 21.2% | 0.0% |
| Healthcare Services | 0.0% | 20.3% |
| Capital Markets | 13.4% | 0.0% |
| Financial Technology (Fintech) | 5.3% | 0.0% |
| Insurance | 3.5% | 0.0% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.0% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Canara Robeco Banking and Financial Services vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Canara Robeco Banking and Financial Services Fund | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.05% | 0.99% |
| Base expense ratio (Direct) | 0.70% | 0.79% |
| Total expense ratio (Regular) | 2.65% | 1.85% |
| Base expense ratio (Regular) | 2.06% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Canara Robeco Banking and Financial Services with
- Canara Robeco Banking and Financial Services vs DSP Healthcare
- Canara Robeco Banking and Financial Services vs Bandhan Transportation and Logistics
- Canara Robeco Banking and Financial Services vs Nippon India Power & Infra
- Canara Robeco Banking and Financial Services vs Invesco India Financial Services
Canara Robeco Banking and Financial Services Fund vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between Canara Robeco Banking and Financial Services Fund and Nippon India Pharma Fund?
Canara Robeco Banking and Financial Services Fund is a Sectoral fund, Nippon India Pharma Fund is a Sectoral fund, run by Canara Robeco Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 0.0%. Canara Robeco Banking and Financial Services Fund charges 1.05% a year and Nippon India Pharma Fund 0.99%.
Which has the lower expense ratio, Canara Robeco Banking and Financial Services Fund or Nippon India Pharma Fund?
Nippon India Pharma Fund charges less: 0.99% a year against 1.05%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Canara Robeco Banking and Financial Services Fund and Nippon India Pharma Fund overlap?
0.0%. They hold 0 of the same securities. From each fund's latest monthly portfolio.
Which is riskier, Canara Robeco Banking and Financial Services Fund or Nippon India Pharma Fund?
On SEBI's riskometer, Canara Robeco Banking and Financial Services Fund is rated Very High and Nippon India Pharma Fund Very High. Over their common history, the standard deviation of daily returns was 15.54% and 15.19% a year.
Can I invest in both Canara Robeco Banking and Financial Services Fund and Nippon India Pharma Fund?
Yes. 0.0% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages Canara Robeco Banking and Financial Services Fund and Nippon India Pharma Fund?
Canara Robeco Banking and Financial Services Fund: Amit Kadam / Mr. Shridatta Bhandwaldar. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.